Analytical Data
-
基因名
Apolipoprotein A-I/APOA1
- Application
-
别名
Apo-A1; ApoA-1 Milano; ProapoA-I; Proapolipoprotein A-I; Truncated apolipoprotein A-I
-
种属
Pig
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
P18648
-
表达区间
Asp25~Gln265
-
分子量
31&70kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Apolipoprotein A-I (APOA1) is a critical protein component of high-density lipoprotein (HDL) and plays a vital role in lipid metabolism and cardiovascular health. It is primarily synthesized in the liver and intestines and is essential for the reverse transport of cholesterol, which helps to prevent atherosclerosis and other cardiovascular diseases. Research into recombinant APOA1 proteins has gained significant attention due to their potential therapeutic applications, including the treatment of metabolic disorders and heart diseases. These recombinant proteins can be produced efficiently using various expression systems, enabling researchers to study their structure, function, and interactions with lipids and receptors. Additionally, recombinant APOA1 has been investigated for its role in enhancing the clearance of excess cholesterol and improving the lipid profiles in patients with dyslipidemia. Ongoing studies focus on the application of APOA1-based therapies in clinical settings, exploring their efficacy in promoting cardiovascular health and potentially serving as biomarkers for assessing cardiovascular risks. Overall, the investigation of recombinant APOA1 opens new avenues for understanding lipid metabolism and developing innovative strategies to combat cardiovascular diseases.
